Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 67 entries
Sorted by: Best Match Show Resources per page
PFKM gene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry.

Neurology. Genetics

Auranen M, Palmio J, Ylikallio E, Huovinen S, Paetau A, Sandell S, Haapasalo H, Viitaniemi K, Piirilä P, Tyynismaa H, Udd B.
PMID: 27066546
Neurol Genet. 2015 Jun 04;1(1):e7. doi: 10.1212/NXG.0000000000000007. eCollection 2015 Jun.

OBJECTIVE: To elaborate the diagnostic methods used as "gold standard" in one of the most common glycogen storage diseases (GSDs), Tarui disease (GSDVII).METHODS: Two siblings with disease suggestive of GSD underwent thorough clinical analysis, including muscle biopsy, muscle MRI,...

Cite
Auranen M, Palmio J, Ylikallio E, et al. PFKM gene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry. Neurol Genet. 2015;1(1):e7doi: 10.1212/NXG.0000000000000007.
Auranen, M., Palmio, J., Ylikallio, E., Huovinen, S., Paetau, A., Sandell, S., Haapasalo, H., Viitaniemi, K., Piirilä, P., Tyynismaa, H., & Udd, B. (2015). PFKM gene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry. Neurology. Genetics, 1(1), e7. https://doi.org/10.1212/NXG.0000000000000007
Auranen, Mari, et al. "PFKM gene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry." Neurology. Genetics vol. 1,1 (2015): e7. doi: https://doi.org/10.1212/NXG.0000000000000007
Auranen M, Palmio J, Ylikallio E, Huovinen S, Paetau A, Sandell S, Haapasalo H, Viitaniemi K, Piirilä P, Tyynismaa H, Udd B. PFKM gene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry. Neurol Genet. 2015 Jun 04;1(1):e7. doi: 10.1212/NXG.0000000000000007. eCollection 2015 Jun. PMID: 27066546; PMCID: PMC4821086.
Copy Download .nbib Format: NLM
[Not Available].

Duodecim; laaketieteellinen aikakauskirja

Raheem O, Suominen T, Hackman P, Vihola A, Auranen M, Kalimo H, Mahjneh I, Kärppä M, Haapasalo H, Udd B.
PMID: 17115630
Duodecim. 2006;122(17):2130-6.

No abstract available.

Cite
Raheem O, Suominen T, Hackman P, et al. Hartia-lantiodystrofioiden molekyyligenetiikka Suomessa. [Not Available]. Duodecim. 2006;122(17):2130-6
Raheem, O., Suominen, T., Hackman, P., Vihola, A., Auranen, M., Kalimo, H., Mahjneh, I., Kärppä, M., Haapasalo, H., & Udd, B. (2006). Hartia-lantiodystrofioiden molekyyligenetiikka Suomessa. [Not Available]. Duodecim; laaketieteellinen aikakauskirja, 122(17), 2130-6.
Raheem, Olayinka, et al. "Hartia-lantiodystrofioiden molekyyligenetiikka Suomessa." [Not Available]. Duodecim; laaketieteellinen aikakauskirja vol. 122,17 (2006): 2130-6.
Raheem O, Suominen T, Hackman P, Vihola A, Auranen M, Kalimo H, Mahjneh I, Kärppä M, Haapasalo H, Udd B. Hartia-lantiodystrofioiden molekyyligenetiikka Suomessa. [Not Available]. Duodecim. 2006;122(17):2130-6. Finnish. PMID: 17115630.
Copy Download .nbib Format: NLM
In vitro antibacterial effect of carbamide peroxide on oral biofilm.

Journal of oral microbiology

Yao CS, Waterfield JD, Shen Y, Haapasalo M, Macentee MI.
PMID: 23785567
J Oral Microbiol. 2013 Jun 12;5. doi: 10.3402/jom.v5i0.20392. Print 2013.

This study compared the effects of carbamide peroxide (CP) and chlorhexidine (CHX) on oral biofilm in vitro. Collagen-coated hydroxyapatite discs were inoculated with subgingival plaque. After 3 weeks, the emergent biofilms were subjected to 1-, 3-, and 10-min exposures...

Cite
Yao CS, Waterfield JD, Shen Y, et al. In vitro antibacterial effect of carbamide peroxide on oral biofilm. J Oral Microbiol. 2013;5doi: 10.3402/jom.v5i0.20392.
Yao, C. S., Waterfield, J. D., Shen, Y., Haapasalo, M., & Macentee, M. I. (2013). In vitro antibacterial effect of carbamide peroxide on oral biofilm. Journal of oral microbiology, 5. https://doi.org/10.3402/jom.v5i0.20392
Yao, Chao Shu, et al. "In vitro antibacterial effect of carbamide peroxide on oral biofilm." Journal of oral microbiology vol. 5 (2013). doi: https://doi.org/10.3402/jom.v5i0.20392
Yao CS, Waterfield JD, Shen Y, Haapasalo M, Macentee MI. In vitro antibacterial effect of carbamide peroxide on oral biofilm. J Oral Microbiol. 2013 Jun 12;5. doi: 10.3402/jom.v5i0.20392. Print 2013. PMID: 23785567; PMCID: PMC3682087.
Copy Download .nbib Format: NLM
Correction: Genotypic and phenotypic diversity of Lactobacillus rhamnosus clinical isolates, their comparison with strain GG and their recognition by complement system.

PloS one

Nissilä E, Douillard FP, Ritari J, Paulin L, Järvinen HM, Rasinkangas P, Haapasalo K, Meri S, Jarva H, de Vos WM.
PMID: 28700750
PLoS One. 2017 Jul 10;12(7):e0181292. doi: 10.1371/journal.pone.0181292. eCollection 2017.

[This corrects the article DOI: 10.1371/journal.pone.0176739.].

Cite
Nissilä E, Douillard FP, Ritari J, et al. Correction: Genotypic and phenotypic diversity of Lactobacillus rhamnosus clinical isolates, their comparison with strain GG and their recognition by complement system. PLoS One. 2017;12(7):e0181292doi: 10.1371/journal.pone.0181292.
Nissilä, E., Douillard, F. P., Ritari, J., Paulin, L., Järvinen, H. M., Rasinkangas, P., Haapasalo, K., Meri, S., Jarva, H., & de Vos, W. M. (2017). Correction: Genotypic and phenotypic diversity of Lactobacillus rhamnosus clinical isolates, their comparison with strain GG and their recognition by complement system. PloS one, 12(7), e0181292. https://doi.org/10.1371/journal.pone.0181292
Nissilä, Eija, et al. "Correction: Genotypic and phenotypic diversity of Lactobacillus rhamnosus clinical isolates, their comparison with strain GG and their recognition by complement system." PloS one vol. 12,7 (2017): e0181292. doi: https://doi.org/10.1371/journal.pone.0181292
Nissilä E, Douillard FP, Ritari J, Paulin L, Järvinen HM, Rasinkangas P, Haapasalo K, Meri S, Jarva H, de Vos WM. Correction: Genotypic and phenotypic diversity of Lactobacillus rhamnosus clinical isolates, their comparison with strain GG and their recognition by complement system. PLoS One. 2017 Jul 10;12(7):e0181292. doi: 10.1371/journal.pone.0181292. eCollection 2017. PMID: 28700750; PMCID: PMC5507318.
Copy Download .nbib Format: NLM
Decreased plasma C-reactive protein levels in .

Annals of clinical and translational neurology

Martiskainen H, Takalo M, Solomon A, Stančáková A, Marttinen M, Natunen T, Haapasalo A, Herukka SK, Kuusisto J, Soininen H, Kivipelto M, Laakso M, Hiltunen M.
PMID: 30349858
Ann Clin Transl Neurol. 2018 Sep 17;5(10):1229-1240. doi: 10.1002/acn3.639. eCollection 2018 Oct.

OBJECTIVE: Apolipoprotein E (METHODS: Association of cardiovascular, metabolic, and inflammation-related parameters with the RESULTS: Individuals carrying the INTERPRETATION: These data suggest that the

Cite
Martiskainen H, Takalo M, Solomon A, et al. Decreased plasma C-reactive protein levels in . Ann Clin Transl Neurol. 2018;5(10):1229-1240doi: 10.1002/acn3.639.
Martiskainen, H., Takalo, M., Solomon, A., Stančáková, A., Marttinen, M., Natunen, T., Haapasalo, A., Herukka, S. K., Kuusisto, J., Soininen, H., Kivipelto, M., Laakso, M., & Hiltunen, M. (2018). Decreased plasma C-reactive protein levels in . Annals of clinical and translational neurology, 5(10), 1229-1240. https://doi.org/10.1002/acn3.639
Martiskainen, Henna, et al. "Decreased plasma C-reactive protein levels in ." Annals of clinical and translational neurology vol. 5,10 (2018): 1229-1240. doi: https://doi.org/10.1002/acn3.639
Martiskainen H, Takalo M, Solomon A, Stančáková A, Marttinen M, Natunen T, Haapasalo A, Herukka SK, Kuusisto J, Soininen H, Kivipelto M, Laakso M, Hiltunen M. Decreased plasma C-reactive protein levels in . Ann Clin Transl Neurol. 2018 Sep 17;5(10):1229-1240. doi: 10.1002/acn3.639. eCollection 2018 Oct. PMID: 30349858; PMCID: PMC6186931.
Copy Download .nbib Format: NLM
Long-term porosity and retreatability of oval-shaped canals obturated using two different methods with a novel tricalcium silicate sealer.

Clinical oral investigations

Zhang W, Liu H, Wang Z, Haapasalo M, Jiang Q, Shen Y.
PMID: 34392407
Clin Oral Investig. 2021 Aug 14; doi: 10.1007/s00784-021-04088-z. Epub 2021 Aug 14.

OBJECTIVE: To evaluate the percentage volume of voids and gaps in oval-shaped canals obturated using two different methods with a tricalcium silicate-based sealer after short- or long-term storage. The long-term effect of storage on the efficiency of removing filling...

Cite
Zhang W, Liu H, Wang Z, et al. Long-term porosity and retreatability of oval-shaped canals obturated using two different methods with a novel tricalcium silicate sealer. Clin Oral Investig. 2021;doi: 10.1007/s00784-021-04088-z.
Zhang, W., Liu, H., Wang, Z., Haapasalo, M., Jiang, Q., & Shen, Y. (2021). Long-term porosity and retreatability of oval-shaped canals obturated using two different methods with a novel tricalcium silicate sealer. Clinical oral investigations, . https://doi.org/10.1007/s00784-021-04088-z
Zhang, Wenjuan, et al. "Long-term porosity and retreatability of oval-shaped canals obturated using two different methods with a novel tricalcium silicate sealer." Clinical oral investigations vol. (2021). doi: https://doi.org/10.1007/s00784-021-04088-z
Zhang W, Liu H, Wang Z, Haapasalo M, Jiang Q, Shen Y. Long-term porosity and retreatability of oval-shaped canals obturated using two different methods with a novel tricalcium silicate sealer. Clin Oral Investig. 2021 Aug 14; doi: 10.1007/s00784-021-04088-z. Epub 2021 Aug 14. PMID: 34392407.
Copy Download .nbib Format: NLM
Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.

Multiple sclerosis and related disorders

Niiranen M, Kontkanen A, Jääskeläinen O, Tertsunen HM, Selander T, Hartikainen P, Huber N, Solje E, Haapasalo A, Kokkola T, Lohioja T, Herukka SK, Simula S, Remes AM.
PMID: 34627002
Mult Scler Relat Disord. 2021 Nov;56:103280. doi: 10.1016/j.msard.2021.103280. Epub 2021 Sep 28.

OBJECTIVE: We aimed to investigate serum glial fibrillary acidic protein (GFAP) and serum neurofilament light chain (NfL) levels as potential discriminative biomarkers between benign relapsing-remitting multiple sclerosis (BRRMS) and aggressive relapsing-remitting MS (ARRMS).METHODS: Serum GFAP and NfL levels were...

Cite
Niiranen M, Kontkanen A, Jääskeläinen O, et al. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;56:103280doi: 10.1016/j.msard.2021.103280.
Niiranen, M., Kontkanen, A., Jääskeläinen, O., Tertsunen, H. M., Selander, T., Hartikainen, P., Huber, N., Solje, E., Haapasalo, A., Kokkola, T., Lohioja, T., Herukka, S. K., Simula, S., & Remes, A. M. (2021). Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. Multiple sclerosis and related disorders, 56103280. https://doi.org/10.1016/j.msard.2021.103280
Niiranen, Marja, et al. "Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis." Multiple sclerosis and related disorders vol. 56 (2021): 103280. doi: https://doi.org/10.1016/j.msard.2021.103280
Niiranen M, Kontkanen A, Jääskeläinen O, Tertsunen HM, Selander T, Hartikainen P, Huber N, Solje E, Haapasalo A, Kokkola T, Lohioja T, Herukka SK, Simula S, Remes AM. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Nov;56:103280. doi: 10.1016/j.msard.2021.103280. Epub 2021 Sep 28. PMID: 34627002.
Copy Download .nbib Format: NLM
S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5.

Neurobiology of disease

Ferreira CB, Marttinen M, Coelho JE, Paldanius KMA, Takalo M, Mäkinen P, Leppänen L, Miranda-Lourenço C, Fonseca-Gomes J, Tanqueiro SR, Vaz SH, Belo RF, Sebastião AM, Leinonen V, Soininen H, Pike I, Haapasalo A, Lopes LV, de Mendonça A, Diógenes MJ, Hiltunen M.
PMID: 34954322
Neurobiol Dis. 2021 Dec 24;163:105603. doi: 10.1016/j.nbd.2021.105603. Epub 2021 Dec 24.

Alzheimer's disease (AD) is the most common form of dementia, which is neuropathologically characterized by extracellular senile plaques containing amyloid-β and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Previous studies have suggested a role for septin (SEPTIN) protein...

Cite
Ferreira CB, Marttinen M, Coelho JE, et al. S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiol Dis. 2021;163:105603doi: 10.1016/j.nbd.2021.105603.
Ferreira, C. B., Marttinen, M., Coelho, J. E., Paldanius, K. M. A., Takalo, M., Mäkinen, P., Leppänen, L., Miranda-Lourenço, C., Fonseca-Gomes, J., Tanqueiro, S. R., Vaz, S. H., Belo, R. F., Sebastião, A. M., Leinonen, V., Soininen, H., Pike, I., Haapasalo, A., Lopes, L. V., de Mendonça, A., Diógenes, M. J., & Hiltunen, M. (2021). S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiology of disease, 163105603. https://doi.org/10.1016/j.nbd.2021.105603
Ferreira, Catarina B, et al. "S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5." Neurobiology of disease vol. 163 (2021): 105603. doi: https://doi.org/10.1016/j.nbd.2021.105603
Ferreira CB, Marttinen M, Coelho JE, Paldanius KMA, Takalo M, Mäkinen P, Leppänen L, Miranda-Lourenço C, Fonseca-Gomes J, Tanqueiro SR, Vaz SH, Belo RF, Sebastião AM, Leinonen V, Soininen H, Pike I, Haapasalo A, Lopes LV, de Mendonça A, Diógenes MJ, Hiltunen M. S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiol Dis. 2021 Dec 24;163:105603. doi: 10.1016/j.nbd.2021.105603. Epub 2021 Dec 24. PMID: 34954322.
Copy Download .nbib Format: NLM
S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5.

Neurobiology of disease

Ferreira CB, Marttinen M, Coelho JE, Paldanius KMA, Takalo M, Mäkinen P, Leppänen L, Miranda-Lourenço C, Fonseca-Gomes J, Tanqueiro SR, Vaz SH, Belo RF, Sebastião AM, Leinonen V, Soininen H, Pike I, Haapasalo A, Lopes LV, de Mendonça A, Diógenes MJ, Hiltunen M.
PMID: 34954322
Neurobiol Dis. 2021 Dec 24;163:105603. doi: 10.1016/j.nbd.2021.105603. Epub 2021 Dec 24.

Alzheimer's disease (AD) is the most common form of dementia, which is neuropathologically characterized by extracellular senile plaques containing amyloid-β and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Previous studies have suggested a role for septin (SEPTIN) protein...

Cite
Ferreira CB, Marttinen M, Coelho JE, et al. S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiol Dis. 2021;163:105603doi: 10.1016/j.nbd.2021.105603.
Ferreira, C. B., Marttinen, M., Coelho, J. E., Paldanius, K. M. A., Takalo, M., Mäkinen, P., Leppänen, L., Miranda-Lourenço, C., Fonseca-Gomes, J., Tanqueiro, S. R., Vaz, S. H., Belo, R. F., Sebastião, A. M., Leinonen, V., Soininen, H., Pike, I., Haapasalo, A., Lopes, L. V., de Mendonça, A., Diógenes, M. J., & Hiltunen, M. (2021). S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiology of disease, 163105603. https://doi.org/10.1016/j.nbd.2021.105603
Ferreira, Catarina B, et al. "S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5." Neurobiology of disease vol. 163 (2021): 105603. doi: https://doi.org/10.1016/j.nbd.2021.105603
Ferreira CB, Marttinen M, Coelho JE, Paldanius KMA, Takalo M, Mäkinen P, Leppänen L, Miranda-Lourenço C, Fonseca-Gomes J, Tanqueiro SR, Vaz SH, Belo RF, Sebastião AM, Leinonen V, Soininen H, Pike I, Haapasalo A, Lopes LV, de Mendonça A, Diógenes MJ, Hiltunen M. S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiol Dis. 2021 Dec 24;163:105603. doi: 10.1016/j.nbd.2021.105603. Epub 2021 Dec 24. PMID: 34954322.
Copy Download .nbib Format: NLM
C9orf72 hexanucleotide repeat expansion leads to altered neuronal and dendritic spine morphology and synaptic dysfunction.

Neurobiology of disease

Huber N, Hoffmann D, Giniatullina R, Rostalski H, Leskelä S, Takalo M, Natunen T, Solje E, Remes AM, Giniatullin R, Hiltunen M, Haapasalo A.
PMID: 34915153
Neurobiol Dis. 2022 Jan;162:105584. doi: 10.1016/j.nbd.2021.105584. Epub 2021 Dec 14.

Frontotemporal lobar degeneration (FTLD) comprises a heterogenous group of progressive neurodegenerative syndromes. To date, no validated biomarkers or effective disease-modifying therapies exist for the different clinical or genetic subtypes of FTLD. The most common genetic cause underlying FTLD and...

Cite
Huber N, Hoffmann D, Giniatullina R, et al. C9orf72 hexanucleotide repeat expansion leads to altered neuronal and dendritic spine morphology and synaptic dysfunction. Neurobiol Dis. 2021;162:105584doi: 10.1016/j.nbd.2021.105584.
Huber, N., Hoffmann, D., Giniatullina, R., Rostalski, H., Leskelä, S., Takalo, M., Natunen, T., Solje, E., Remes, A. M., Giniatullin, R., Hiltunen, M., & Haapasalo, A. (2022). C9orf72 hexanucleotide repeat expansion leads to altered neuronal and dendritic spine morphology and synaptic dysfunction. Neurobiology of disease, 162105584. https://doi.org/10.1016/j.nbd.2021.105584
Huber, Nadine, et al. "C9orf72 hexanucleotide repeat expansion leads to altered neuronal and dendritic spine morphology and synaptic dysfunction." Neurobiology of disease vol. 162 (2022): 105584. doi: https://doi.org/10.1016/j.nbd.2021.105584
Huber N, Hoffmann D, Giniatullina R, Rostalski H, Leskelä S, Takalo M, Natunen T, Solje E, Remes AM, Giniatullin R, Hiltunen M, Haapasalo A. C9orf72 hexanucleotide repeat expansion leads to altered neuronal and dendritic spine morphology and synaptic dysfunction. Neurobiol Dis. 2022 Jan;162:105584. doi: 10.1016/j.nbd.2021.105584. Epub 2021 Dec 14. PMID: 34915153.
Copy Download .nbib Format: NLM
S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5.

Neurobiology of disease

Ferreira C, Marttinen M, Coelho JE, Paldanius KMA, Takalo M, Mäkinen P, Leppänen L, Miranda-Lourenço C, Fonseca-Gomes J, Tanqueiro SR, Vaz SH, Belo RF, Sebastião AM, Leinonen V, Soininen H, Pike I, Haapasalo A, Lopes LV, de Mendonça A, Diógenes MJ, Hiltunen M.
PMID: 34954322
Neurobiol Dis. 2021 Dec 23;105603. doi: 10.1016/j.nbd.2021.105603. Epub 2021 Dec 23.

Alzheimer's disease (AD) is the most common form of dementia, which is neuropathologically characterized by extracellular senile plaques containing amyloid-β and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Previous studies have suggested a role for septin (SEPTIN) protein...

Cite
Ferreira C, Marttinen M, Coelho JE, et al. S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiol Dis. 2021;105603doi: 10.1016/j.nbd.2021.105603.
Ferreira, C., Marttinen, M., Coelho, J. E., Paldanius, K. M. A., Takalo, M., Mäkinen, P., Leppänen, L., Miranda-Lourenço, C., Fonseca-Gomes, J., Tanqueiro, S. R., Vaz, S. H., Belo, R. F., Sebastião, A. M., Leinonen, V., Soininen, H., Pike, I., Haapasalo, A., Lopes, L. V., de Mendonça, A., Diógenes, M. J., & Hiltunen, M. (2021). S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiology of disease, 105603. https://doi.org/10.1016/j.nbd.2021.105603
Ferreira, CatarinaB, et al. "S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5." Neurobiology of disease vol. (2021): 105603. doi: https://doi.org/10.1016/j.nbd.2021.105603
Ferreira C, Marttinen M, Coelho JE, Paldanius KMA, Takalo M, Mäkinen P, Leppänen L, Miranda-Lourenço C, Fonseca-Gomes J, Tanqueiro SR, Vaz SH, Belo RF, Sebastião AM, Leinonen V, Soininen H, Pike I, Haapasalo A, Lopes LV, de Mendonça A, Diógenes MJ, Hiltunen M. S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiol Dis. 2021 Dec 23;105603. doi: 10.1016/j.nbd.2021.105603. Epub 2021 Dec 23. PMID: 34954322.
Copy Download .nbib Format: NLM
GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance.

Journal of neurology, neurosurgery, and psychiatry

Katisko K, Cajanus A, Huber N, Jääskeläinen O, Kokkola T, Kärkkäinen V, Rostalski H, Hartikainen P, Koivisto AM, Hannonen S, Lehtola JM, Korhonen VE, Helisalmi S, Koivumaa-Honkanen H, Herukka SK, Remes AM, Solje E, Haapasalo A.
PMID: 34187866
J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305-1312. doi: 10.1136/jnnp-2021-326487. Epub 2021 Jun 29.

BACKGROUND: Frontotemporal lobar degeneration (FTLD) and primary psychiatric disorders (PPD) are characterised by overlapping clinical features but different aetiologies. Here, we assessed for the first time the potential of blood glial fibrillar acidic protein (GFAP), marker of astrogliosis, as...

Cite
Katisko K, Cajanus A, Huber N, et al. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry. 2021;92(12):1305-1312doi: 10.1136/jnnp-2021-326487.
Katisko, K., Cajanus, A., Huber, N., Jääskeläinen, O., Kokkola, T., Kärkkäinen, V., Rostalski, H., Hartikainen, P., Koivisto, A. M., Hannonen, S., Lehtola, J. M., Korhonen, V. E., Helisalmi, S., Koivumaa-Honkanen, H., Herukka, S. K., Remes, A. M., Solje, E., & Haapasalo, A. (2021). GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. Journal of neurology, neurosurgery, and psychiatry, 92(12), 1305-1312. https://doi.org/10.1136/jnnp-2021-326487
Katisko, Kasper, et al. "GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance." Journal of neurology, neurosurgery, and psychiatry vol. 92,12 (2021): 1305-1312. doi: https://doi.org/10.1136/jnnp-2021-326487
Katisko K, Cajanus A, Huber N, Jääskeläinen O, Kokkola T, Kärkkäinen V, Rostalski H, Hartikainen P, Koivisto AM, Hannonen S, Lehtola JM, Korhonen VE, Helisalmi S, Koivumaa-Honkanen H, Herukka SK, Remes AM, Solje E, Haapasalo A. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305-1312. doi: 10.1136/jnnp-2021-326487. Epub 2021 Jun 29. PMID: 34187866.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 67 entries